a 2020

EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P2)

GRATACOS-MASMITJA, J., A. TURKIEWICZ, Eva DOKOUPILOVÁ, A. M. GELLETT, T. SPRABERY et. al.

Basic information

Original name

EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P2)

Authors

GRATACOS-MASMITJA, J., A. TURKIEWICZ, Eva DOKOUPILOVÁ (203 Czech Republic, belonging to the institution), A. M. GELLETT, T. SPRABERY, V. J, GENEUS and A. CONSTANTIN

Edition

2020

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

RIV identification code

RIV/00216224:14160/20:00118264

Organization unit

Faculty of Pharmacy

DOI

UT WoS

000555905003485

Keywords in English

efficacy; safety; ixekizumab; patients; psoriatic arthritis; inadequate response; inhibitors

Tags

Tags

International impact, Reviewed
Změněno: 30/8/2022 14:47, JUDr. Sabina Krejčiříková

Abstract

V originále

Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A. In the SPIRIT-P2 study, IXE every 4 (Q4W) or 2 (Q2W) weeks was superior to placebo (PBO) in improving the signs and symptoms of psoriatic arthritis (PsA) at Week 24 in patients (pts) with prior inadequate response or intolerance to 1 or 2 tumor necrosis factor inhibitors (TNFi).